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Research has shown that approximately one in three Americans suffer from chronic 
pain, with an annual cost of $560 to $635 billion from associated healthcare costs and 
lost productivity (Cruz et al, 2015). Historically, physicians have attempted to manage 
pain by using opioid-based analgesics which include medications like oxycodone and 
hydrocodone. Patients commonly report that pain medication becomes less effective 
over time, even with dose escalations and polypharmacy. Furthermore, the conse-
quences of long-term opioid use are numerous, including over 16,000 related deaths 
annually. This has driven more pain management physicians to seek alternative treatment 
modalities, such as spinal cord stimulation (SCS). SCS is an invasive therapy used to 
provide pain relief for multiple types of chronic pain diagnoses when conservative and 
medical therapies fail.
Spinal cord stimulation is achieved by the introduction of electrical current to the painful 
area providing a more pleasant sensation, replacing the painful sensation; this is done 
by introducing a thin flexible electrode into the epidural space, which will then be used 
to stimulate specific targets to treat a variety of pain disorders. SCS is the number one 
indication in the treatment of chronic pain despite having spinal surgery, also known as 
“failed back surgery syndrome” (FBSS). Prospective randomized studies in patients who 
are candidates for a second spine surgery have shown to do better with SCS with pain 
reduction, health care utilization, and crossover to additional therapies and long-term 
costs (Deer, 2010). SCS is also used to manage pain from chronic regional pain syndrome 
(CRPS), ischemic limb pain, neuropathy, and cervical or lumbar persistent radiculopathy. 
The use of neuromodulation for pain relief is among the fastest growing areas of medi-
cine, involving many diverse specialties and impacting thousands of patients with various 
ailments. Historically, electricity, whether as a torpedo fish or man-made electrotherapy, 
has been used to try and cure these ailments. The modern era of neuromodulation 
began in the early 1960s, first with deep brain stimulation soon followed by spinal cord 
stimulation. In 1965, Melzack and Wall proposed the “gate theory” which postulated 
that pain perception involves a gate that can be opened or closed depending on the 
balance between firing of small and large neural fibers (Gildenberg, 2006). This concept 
was tested and eventually led to the development of the first implantable stimulator in 
1967, which was used to treat chronic pain with peripheral nerve stimulation. However, 
the Gate Theory has not been fully adequate in explaining the full complexity of SCS 
in neuromodulation. 
SCS, as well as other implantable devices in neuromodulation, have made great advances 
in technology over the past 4 decades. The leads have evolved from monopolar stimula-
tion to multi-contact lead arrays. Programming SCS has become more creative, from 
simple monopolar fields to complex programming options to cover multiple painful 
areas. The generators have evolved from large and non-rechargeable for limb pain or 
cumbersome radiofrequency devices with an external power sources required if you 
had back and limb pain to smaller internal generators that can be recharged. Patients 
have greater freedom to place the generator in different areas of the body, such as the 
buttock, chest wall, or axilla. More recently, patients now have the option to choose 
devices that are MRI-compatible with certain manufacturer restrictions.
Conventional SCS (or tonic stimulation) 
creates a paresthesia sensation overlying 
the patient’s area of pain. More recently, 
SCS advancements now include high-
frequency stimulation (HF10), burst 
stimulation, and dorsal root ganglion 
(DRG) stimulation. This evolution has led 
to greater pain relief and better patient 
reported outcomes. There are many 
benefits in choosing one form of therapy 
over the other; however, the goal is to 
choose the system that best addresses the 
patient’s needs and will lead to a favorable 
outcome. From a patient’s standpoint, the 
therapy should provide the best option 
of reducing pain and improving quality 
of life.
The SCS device consists of electrode 
leads, extension cable, a pulse generator, 
and a programmer. The leads can be 
percutaneous, paddle, or a hybrid of 
both. Percutaneous leads, placed by a 
pain physician, neurosurgeon or ortho-
pedic surgeon, are introduced into the 
epidural space via a needle under fluoro-
scopic guidance, while paddle leads are 
generally placed by a neurosurgeon or an 
orthopedic surgeon via an open proce-
dure that would involve a laminotomy 
or laminectomy. Prior to implantation, 
patients undergo a temporary trial, 
usually lasting anywhere from 3 to 10 
days. During this trial, the clinician targets 
the patient’s pain by inserting the leads 
over the appropriate level of the spinal 
cord. The leads are connected to an 
external battery back wrapped securely 
to the patient. The patient then monitors 
pain relief with usual daily activities and 
documents this in a diary. At the comple-
tion of the trial, the leads are removed in 
the office and both the clinician and the 
patient will discuss the patient’s response 
to the SCS. A successful trial is deter-
mined if >50% reduction in baseline pain 
is achieved. It is important that the patient 
establish realistic goals and expectations 
prior to the SCS trial and is satisfied with 
the results of trial prior to proceeding with 
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satisfaction and clinically significant gains 
in functional capacity and quality of life. 
The advancements in SCS have led to 
more patient-friendly options that do 
not allow the therapy to interfere with a 
patient’s function but will allow for more 
flexibility. Earlier introduction of SCS in 
the pain management algorithm that 
focuses on individualized pain therapy 
can lead to better long-term outcomes 
for the patient. Ultimately, patients should 
be well-informed of the available options 
that would best suit his or her needs. 
a permanent implantation. SCS is a rela-
tively safe procedure and reversible with 
implant removal. Adverse events were 
reported between 34% and 38% (Song et 
al, 2014). The most commonly reported 
complication was lead migration and/or 
breakage.
Published studies have shown that when 
used by properly selected patients, SCS 
therapy is successful in managing chronic 
pain. Kumar et al. (2008) found that in 
selected patients with FBSS, treatment 
with SCS results in pain relief sustained at 
24 months and is associated with patient 
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